



(11) **EP 2 691 534 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
G01N 33/53 (2006.01) **G01N 33/574** (2006.01)
G01N 33/68 (2006.01) **G01N 33/74** (2006.01)

(48) Corrigendum issued on:
11.10.2017 Bulletin 2017/41

(86) International application number:
PCT/US2012/026141

(45) Date of publication and mention
of the grant of the patent:
26.07.2017 Bulletin 2017/30

(87) International publication number:
WO 2012/141792 (18.10.2012 Gazette 2012/42)

(21) Application number: **12771223.0**

(22) Date of filing: **22.02.2012**

(54) **ADIPONECTIN RECEPTOR C-TERMINAL FRAGMENTS (CTF)-IMMUNOGLOBULIN**
IMMUNOGLOBULIN MIT ADIPONEKTIN-REZEPTOR-C-TERMINAL-FRAGMENTEN (CTF)
FRAGMENTS C-TERMINAUX (CTF) DE RÉCEPTEUR D'ADIPONECTINE-IMMUNOGLOBULINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **11.04.2011 US 201161445103 P**

(43) Date of publication of application:
05.02.2014 Bulletin 2014/06

(73) Proprietor: **Siemens Healthcare Diagnostics Inc.**
Tarrytown, NY 10591-5098 (US)

(72) Inventor: **PUGIA, Michael**
Granger, IN 46530 (US)

(74) Representative: **Schweitzer, Klaus et al**
Plate Schweitzer Zounek
Patentanwälte
Rheingastrasse 196
65203 Wiesbaden (DE)

(56) References cited:
EP-A1- 1 870 710 WO-A1-2010/123720
WO-A2-2005/001061 US-A1- 2008 221 305
US-A1- 2010 143 958 US-A1- 2010 143 958

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 691 534 B8